Tag Archive for: TG Therapeutics

New long-term and real-world data on BRIUMVI® (ublituximab) presented at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026

/in

New scientific data in relapsing forms of multiple sclerosis (RMS) were presented across a series of poster presentations led by MS experts Data presented at MSToronto2026 reinforce the growing body of evidence supporting the therapy, with more than 30,000 patients treated worldwide1 Barcelona, Spain, and Düsseldorf, Germany – 23 October 2026 – Neuraxpharm Group (Neuraxpharm), […]

Read more

New ublituximab data in multiple sclerosis to be presented at ECTRIMS Congress 2025 alongside partner TG Therapeutics

/in

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces its participation at 41st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Annual Congress, taking place in Barcelona from 24–26 September. […]

Read more

Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis

/in

Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow Only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion*, twice per year** Launch follows ex-US commercialisation*** agreement with TG Therapeutics announced August 2023 Barcelona and Düsseldorf – 26 February 2024 – Neuraxpharm Group […]

Read more

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

/in

Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted within the next six months TG retains strategic flexibility with an option to buy back all rights under this agreement if TG is […]

Read more
© Optimum Strategic Communications.